Astrocytes and Gliotransmitters: New Players in the Treatment of Major Depression?

E-ISSN： 1873-5592|14|11|1295-1307

ISSN： 1389-4501

Source： Current Drug Targets, Vol.14, Iss.11, 2013-10, pp. : 1295-1307

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Editorial (Thematic Issue: Glia: A New Cellular Target in the Treatment of Major Depression)

Current Drug Targets, Vol. 14, Iss. 11, 2013-01 ,pp. : 1219-1219

Bentham Science Publishers

Access to resources Recommend Favorite

Catecholaminergic Strategies for the Treatment of Major Depression

Current Drug Targets, Vol. 7, Iss. 2, 2006-02 ,pp. : 149-158

Bentham Science Publishers

Access to resources Recommend Favorite

Augmentation Strategies to Improve Treatment of Major Depression

Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Central Nervous System Agents), Vol. 6, Iss. 2, 2006-01 ,pp. : 135-152

Bentham Science Publishers

Access to resources Recommend Favorite

A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression

By Howland Robert H.

Drug Safety, Vol. 34, Iss. 9, 2011-09 ,pp. : 709-731

Adis International

Access to resources Recommend Favorite

A review of the efficacy and tolerability of agomelatine in the treatment of major depression

By Ghosh Anita Hellewell Jonathan SE

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 12, 2007-12 ,pp. : 1999-2004

Informa Healthcare

Access to resources Recommend Favorite